Skip to main content
MBI logo

MBI — Investor Relations & Filings

Ticker · 1783 ISIN · TW0001783009 TW Manufacturing
Open in API
Filings indexed 1,694 across all filing types
Latest filing 2024-10-08 Director's Dealing
Country TW Taiwan
Listing TW 1783

About MBI

www.mbi.com.tw

Maxigen Biotech Inc. (MBI) is a medical device manufacturer specializing in the research, development, and production of biopolymer-based solutions, primarily focusing on collagen matrix and hyaluronic acid technologies. The company provides a comprehensive range of medical devices across multiple clinical disciplines, including orthopedics, aesthetics, ophthalmology, and wound care. Key products include hyaluronic acid intra-articular injections, dermal fillers, ophthalmic viscoelastics, collagen wound dressings, dental membranes, and synthetic bone grafts. In addition to its proprietary brands, MBI offers global OEM/ODM and customization services. The company adheres to international quality standards, holding certifications such as CE, FDA, NMPA, and MDSAP. MBI leverages its expertise in biopolymer science to deliver innovative medical and skincare products to international markets.

Recent filings

Filing Released Lang Actions
113年09月內部人持股異動(事後)
Director's Dealing Classification · 100% confidence The document consists of detailed tables listing shareholdings and changes in share ownership by insiders, including directors, chairpersons, general managers, and other key personnel. It includes data on shares held at appointment, changes during the month, and current holdings, with specific notes on identities and relationships. The content is focused on insider share transactions and holdings rather than financial results, management changes, or other corporate events. There is no indication of a full financial report, earnings release, or meeting materials. This type of document aligns with reporting of personal share transactions by company directors and executives, which corresponds to the 'Director's Dealing' category.
2024-10-08 Chinese
113年09月董事會成員及持股
Director's Dealing Classification · 95% confidence The document is a detailed tabulation of shareholdings by company insiders, including directors, independent directors, general manager, and other key personnel. It lists the number of shares held, pledged shares, and related information. The document does not contain financial statements, earnings data, or management discussion. It is a disclosure of insider shareholdings and related information. This type of document corresponds to Director's Dealing (DIRS), which reports personal share transactions or holdings by company directors and executives. The document length is about 3,000 characters, which is consistent with a detailed insider shareholding report rather than a brief announcement or a full financial report. Therefore, the appropriate classification is DIRS with high confidence.
2024-10-08 Chinese
公告本公司發言人異動
Board/Management Information Classification · 95% confidence The document is a short announcement (741 characters) about a change in the company's spokesperson, detailing the old and new spokespersons, their titles, and the effective date. It does not contain financial data, report content, or regulatory filings beyond the personnel change. This fits the definition of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management positions. The document is not a report or a report publication announcement, nor is it a certification or other regulatory filing. Therefore, the correct classification is MANG with high confidence.
2024-10-07 Chinese
113年9月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a brief financial disclosure from a listed company, 和康生, providing data on fund lending balances and endorsement guarantees for the current and previous month. It contains tabular financial data but is very short (612 characters) and does not include comprehensive financial statements or detailed analysis. It appears to be a regulatory disclosure of specific financial information rather than a full report or announcement of a report. There is no indication of an annual or interim report, audit report, or other detailed filings. Given the nature and brevity, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory disclosures that do not fit other specific categories.
2024-10-05 Chinese
113年9月營業收入
Fund Information / Factsheet Classification · 90% confidence The document is a summarized revenue report for a company named 和康生 for the month and year-to-date period ending in 民國113年09月 (September 2024). It contains numerical data on net operating revenue, comparisons to the previous year, and notes on accounting standards (IFRS) and reporting requirements. The document is very short (765 characters) and primarily provides a brief financial summary without detailed financial statements or management discussion. It does not appear to be a full financial report like an Annual Report (10-K) or Interim Report (IR). It also does not fit categories like Earnings Release (ER) because it lacks key highlights or narrative. It is not a presentation or a regulatory filing announcement. Given the nature of the data as a brief financial summary, this best fits the category of Fund Information / Factsheet (FS), which is defined as a brief (1-2 page) summary of key company facts and financials. Confidence is high due to the clear match with the brief financial summary format and content.
2024-10-05 Chinese
113年08月內部人持股異動(事後)
Director's Dealing Classification · 100% confidence The document consists of detailed tables listing shareholdings and changes in share ownership by insiders, including directors, chairpersons, general managers, and other key personnel. It includes specific data on shares held, increases, decreases, and trust shares. The content is focused on insider share transactions and holdings rather than financial results, management changes, or other corporate events. There is no indication of this being a report or announcement of a report, nor is it a transcript or presentation. The document is a detailed insider shareholding disclosure, which aligns with the definition of Director's Dealing (DIRS).
2024-09-09 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.